All In Biotech

Drug Trial Radar · NCT03602859

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,400 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,400

Actual

Start

Oct 11, 2018

Primary completion

Oct 31, 2024

Study completion Apr 30, 2029

Sponsor

Lead sponsor
Tesaro, Inc.GSK (GSK)
Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT)
First posted
Jul 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression, and deoxyribonucleic acid (DNA) damage in ovarian tumors provide several targets for treatment and maintenance of disease response. Given the unmet medical need of participants with advanced or metastatic ovarian cancer, this study design will enable investigators to provide participants with current SOC for ovarian cancer for the duration of the study. This is a global, multicenter, randomized, double-blind, controlled Phase 3 study that will primarily compare the progression-free survival (PFS) for participants receiving dostarlimab with SOC chemotherapy +/- bevacizumab followed by niraparib and dostarlimab maintenance +/- bevacizumab versus participants receiving SOC with chemotherapy followed by niraparib maintenance. This comparison will be investigated in participants of newly diagnosed stage III or IV advanced non-mucinous epithelial ovarian cancer participants and also to compare PFS of all participants with Stage III or IV high-grade non-mucinous epithelial ovarian cancer treated with platinum-based combination therapy, dostarlimab (TSR-042), and niraparib to SOC platinum-based combination therapy. The currently recommended SOC therapy for the first line treatment of Stage III or IV ovarian cancer is the combination of paclitaxel and carboplatin, with or without concurrent and maintenance bevacizumab. Participants will receive SOC during the chemotherapy Run-In period (cycle 1) before randomization to study treatment (cycle 2). Concurrent bevacizumab use must be determined prior to randomization at cycle 2.

Conditions

  • Ovarian Neoplasms
  • Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

Interventions

  • NiraparibDrug

    Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg)

  • Dostarlimab (TSR-042)Drug

    Participants will receive 500 mg dostarlimab on day 1 every 3 weeks from cycle 2 to 6 followed by 1000mg of dostarlimab on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision

  • Standard of careDrug

    Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.

  • Dostarlimab-PlaceboDrug

    Participants will receive 500 mg of dostarlimab-placebo on day 1 every 3 weeks from cycle 2 to 6 followed by 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision

  • Niraparib-PlaceboDrug

    Participants will receive oral capsules of niraparib-placebo as a unit dosage strength of 100 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to approximately 316 weeks

Locations

182 sites in 19 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Anchorage, Alaska

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Newport Beach, California

  • GSK Investigational Site

    Farmington, Connecticut

  • GSK Investigational Site

    Hartford, Connecticut

  • GSK Investigational Site

    Gainesville, Florida

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Geneva, Illinois

  • GSK Investigational Site

    Warrenville, Illinois

  • GSK Investigational Site

    Zion, Illinois

  • GSK Investigational Site

    Covington, Louisiana

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Shreveport, Louisiana

  • GSK Investigational Site

    Scarborough, Maine

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Silver Spring, Maryland

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Springfield, Massachusetts

  • GSK Investigational Site

    Worcester, Massachusetts

  • GSK Investigational Site

    Minneapolis, Minnesota

  • GSK Investigational Site

    Minneapolis, Minnesota

  • GSK Investigational Site

    Billings, Montana

  • GSK Investigational Site

    Neptune City, New Jersey

  • GSK Investigational Site

    Teaneck, New Jersey

  • GSK Investigational Site

    Hawthorne, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Rochester, New York

  • GSK Investigational Site

    Stony Brook, New York

  • GSK Investigational Site

    Syracuse, New York

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Canton, Ohio

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Oklahoma City, Oklahoma

  • GSK Investigational Site

    Eugene, Oregon

  • GSK Investigational Site

    Portland, Oregon

Showing 40 of 182 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.